BIO-THERA SOLUTIONS, LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.39 CNY | -4.90% |
|
-6.52% | -33.58% |
| May. 10 | China Grants Clinical Trial Approval to Bio-Thera's Anti-Tumor Combination Therapy | MT |
| Apr. 29 | Bio-Thera Solutions, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 1.49B 206M | Sales 2025 * | 2.48B 343M | Capitalization | 11.34B 1.57B |
|---|---|---|---|---|---|
| Net income 2024 * | -22M -3.04M | Net income 2025 * | 571M 78.86M | EV / Sales 2024 * | 7.61 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.57 x |
| P/E ratio 2024 * |
-548
x | P/E ratio 2025 * |
19.8
x | Employees | 1,167 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 20.8% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.90% | ||
| 1 week | -6.52% | ||
| Current month | -17.30% | ||
| 1 month | -7.72% | ||
| 3 months | -20.42% | ||
| 6 months | -31.16% | ||
| Current year | -33.58% |
1 week
27.18
30.81
1 month
27.1835.78
Current year
24.0341.92
1 year
24.0347.46
3 years
17.0947.46
5 years
17.0978.00
10 years
17.0978.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sheng Feng Li
CEO | Chief Executive Officer | 65 | 03-07-27 |
Xian Hong Zhan
DFI | Director of Finance/CFO | 46 | 19-04-18 |
Xiao Yun Wu
CHM | Chairman | 43 | 10-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
De Han Huang
BRD | Director/Board Member | 59 | 22-05-19 |
Sheng Feng Li
CEO | Chief Executive Officer | 65 | 03-07-27 |
Jin Chen Yu
BRD | Director/Board Member | 66 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 27.39 | -4.90% | 1,907,410 |
| 24-05-22 | 28.8 | -1.13% | 1,100,400 |
| 24-05-21 | 29.13 | -2.25% | 927,377 |
| 24-05-20 | 29.8 | -1.06% | 1,396,690 |
| 24-05-17 | 30.12 | +2.80% | 1,374,216 |
End-of-day quote Shanghai S.E., May 22, 2024
More quotes
Bio-Thera Solutions, Ltd. is a China-based company mainly engaged in the research and development of innovative drugs and biosimilars. The Company is committed to the development of a new generation of antibody drugs to treat cancer, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life and health. The Company's main products include adalimumab BAT1406, bevacizumab BAT1706, BAT8001, tocilizumab BAT1806, batifaban BAT2094, BAT8003 and so on.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
27.39
CNY
Average target price
54
CNY
Spread / Average Target
+97.15%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.58% | 1.65B | |
| +10.79% | 115B | |
| +11.65% | 106B | |
| -6.20% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.41% | 17.56B | |
| -40.50% | 17.32B | |
| +6.64% | 14.03B | |
| +31.84% | 12.13B |
- Stock Market
- Equities
- 688177 Stock
